Carnegie acted as sole global co-ordinator and sole bookrunner in the directed new share issue of approx. 3.9 million shares at a subscription price of GBP 190 pence (EUR 2.198) per share. Faron (LONDON AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response, in oncology and organ damage. Faron is based in Turku, Finland. November 2019.